real-world evidence

RWE: Better Research Demands Better Privacy

This is the second in a five-part blog series focusing on how life sciences companies can establish leadership in the…

4 Considerations for Taking the Lead in Real-World Evidence

This is the first in a five-part blog series focusing on how life sciences companies can establish leadership in the…

RWE and Risk: A Primer

Balancing the Demand for Deep Data with Patient Privacy As pharma companies have become more sophisticated in their use of…

Final Thoughts on RWE

The last few weeks we have been focusing on the benefits of Real World Evidence (RWE). In these final thoughts,…

Building a De-identification Pipeline to Support RWE

To use patient-level data for RWE initiatives, biopharmaceutical companies must first obtain the patient’s consent that their data can be…

Using RWE Across the Drug Product Lifecycle

In addition to providing insights about comparative effectiveness and pharmacovigilance, drug makers are being spurred to consider real world evidence…

The Limitations on Learning from Clinical Trials

One of the many benefits from RWE can be realized when you look at the limitations on learning from clinical…

The Rising Demand for RWE

In light of our recent acquisition by IMS, Privacy Analytics’ value as the provider of de-identification and anonymization software and…

Privacy Analytics now part of IMS Health

We’d like to announce that IMS Health (NYSE: IMS) has acquired Privacy Analytics. IMS Health is a leading global information…

IMS Brogan Case Study

Unlocking the Value of EMR Data for Advanced Research and Analysis, Better Health Metrics, and Product Innovation

Free Webinar: De-Identification 101

Join Privacy Analytics for a high level introduction of de-identification and data masking.
Watch now

Free Download: De-Id 101

You have Successfully Subscribed!